An orally bioavailable antagonist of CCR5 and CCR2 (IC50s = 2.3 and 5.9 nM, respectively, for receptors in CHO cells); an antagonist of CCR3 and CCR4 (IC50s = 2.4 and 1.1 μM, respectively); completely inhibits replication of R5 HIV-1 in U87.CD4.CCR5 cells (100 nM); inhibits replication of the R5 HIV-1 strains JR-FL and KK in PBMCs (EC50s = 21-210 pM and 33-91 pM, respectively); reduces collagen deposition, levels of collagen type 1 protein and mRNA expression, and non-alcoholic fatty liver disease activity score in a mouse model of NASH (20 mg/kg per day); reduces collagen type 1 protein levels, mRNA expression, and collagen deposition in a mouse model of unilateral ureter obstruction and a rat model of thioacetamide-induced liver fibrosis